Missouri Judge Approves $7.25 Billion Bayer Roundup Cancer Settlement
A Missouri judge on Friday approved a nationwide class-action settlement worth up to $7.25 billion that will resolve most U.S. cancer claims over Bayer's Roundup weed killer, a ruling that reshapes the legal and financial stakes for the company and hundreds of thousands of users.[1]
St. Louis Circuit Judge Timothy Boyer signed off on the agreement, which will pay out over roughly 21 years to people already diagnosed with non-Hodgkin lymphoma and to those who are diagnosed in the future after past Roundup exposure, with projected average individual awards ranging from about $10,000 to $165,000 depending on age, exposure and disease severity.[1] Bayer CEO Bill Anderson hailed the decision as a "decisive milestone" in managing the company's Roundup litigation risk, even as the company continues to maintain that the herbicide, whose active ingredient is glyphosate, does not cause cancer.[1]
Roundup, developed by Monsanto and later acquired by Bayer, became one of the world's most widely used weed killers, particularly in agriculture and home gardening, before it turned into a legal and public-relations crisis after studies and cancer patients alleged a link to non-Hodgkin lymphoma.[1] Juries began awarding multibillion-dollar verdicts to individual plaintiffs several years ago, though many awards were later reduced on appeal, while federal regulators such as the Environmental Protection Agency have repeatedly said glyphosate is unlikely to cause cancer at typical exposure levels.[1] The clash between courtroom outcomes and regulatory assessments helped push both sides toward a comprehensive settlement structure that could cap Bayer's exposure while offering standardized compensation to a large pool of past and future claimants.
A key legal turning point came in June 2026, when the U.S. Supreme Court ruled that federal pesticide-labeling law preempts state failure-to-warn lawsuits over Roundup, sharply limiting one of the main legal theories plaintiffs had used in state courts and strengthening Bayer's hand in settlement negotiations.[1] With that pathway largely closed, plaintiffs' lawyers increasingly focused on securing a national class deal that would bring consistency to payouts and ensure that people who may develop non-Hodgkin lymphoma in years to come can still seek compensation without relitigating whether Roundup's label was adequate each time.[1]
The settlement's tiered payout formula is designed to prioritize younger workers with heavy, long-term exposure and aggressive forms of non-Hodgkin lymphoma, reflecting evidence that risk appears higher among people who used Roundup frequently and intensively in agricultural or professional settings.[1] Consumer and farmworker advocates say that structure provides a more predictable, if sometimes modest, path to compensation than the litigation lottery of individual trials, but they also warn that many families could see awards that fall far short of medical bills, lost wages and pain and suffering, especially for lower-income or older claimants whose projected payments sit at the bottom of the range.[1]
Bayer's insistence that Roundup is safe, even as it pays out billions of dollars, underscores the unresolved scientific and regulatory debate that will continue beyond this settlement, including questions about whether the company should change product labels, reformulate glyphosate-based herbicides, or phase out certain uses to avoid future health concerns.[1] For farmers and landscapers who rely on Roundup, the ruling offers legal clarity but not necessarily a clear answer on long-term health risks, while for Bayer investors it reduces one of the company's most unpredictable liabilities, even as potential litigation in other countries and over other Monsanto legacy products still looms.[1]
Show source details & analysis (1 source)
📌 Key Facts
- On Friday, November 20, 2026, St. Louis Circuit Judge Timothy Boyer approved a nationwide Roundup settlement worth up to $7.25 billion over about 21 years.
- The class deal covers U.S. users already diagnosed with non-Hodgkin lymphoma and those diagnosed in future years after past Roundup exposure.
- Average payouts are projected between roughly $10,000 and $165,000, with higher amounts for younger, heavily exposed workers with aggressive disease.
- Bayer CEO Bill Anderson called the ruling a decisive milestone in managing Roundup litigation risk, while the company maintains Roundup does not cause cancer.
- The settlement follows a June 2026 U.S. Supreme Court decision holding that Bayer cannot be sued in state courts for failure-to-warn claims preempted by federal labeling law.
📰 Source Timeline (1)
Follow how coverage of this story developed over time